LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.62 -2.99

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.6099999999999999

Max

1.76

Põhinäitajad
By Trading Economics
Sissetulek	-2.8M -16M
Müük	-8.7M 5.5M
Kasumimarginaal	-282.723
Töötajad	103
EBITDA	-4.2M -15M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+121.05% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	60M 712M
Eelmine avamishind	4.61
Eelmine sulgemishind	1.62

Uudiste sentiment

By Acuity

50%

146 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. märts 2026, 20:38 UTC

Tulu

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10. märts 2026, 23:57 UTC

Market Talk

Global Equities Roundup: Market Talk

10. märts 2026, 23:57 UTC

Market Talk

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10. märts 2026, 23:47 UTC

Market Talk

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10. märts 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10. märts 2026, 23:06 UTC

Tulu

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10. märts 2026, 22:51 UTC

Uudisväärsed sündmused

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10. märts 2026, 21:39 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10. märts 2026, 21:21 UTC

Tulu

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10. märts 2026, 21:15 UTC

Tulu

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10. märts 2026, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10. märts 2026, 21:14 UTC

Tulu

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10. märts 2026, 21:13 UTC

Tulu

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10. märts 2026, 21:12 UTC

Tulu

Franco-Nevada 4Q Rev $597.3M >FNV

10. märts 2026, 21:12 UTC

Tulu

Franco-Nevada 4Q EPS $1.90

10. märts 2026, 20:57 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10. märts 2026, 20:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

10. märts 2026, 20:44 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10. märts 2026, 20:34 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

10. märts 2026, 20:34 UTC

Market Talk

Tulu

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10. märts 2026, 20:23 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10. märts 2026, 20:16 UTC

Tulu

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10. märts 2026, 20:14 UTC

Tulu

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10. märts 2026, 20:14 UTC

Tulu

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10. märts 2026, 20:13 UTC

Tulu

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10. märts 2026, 20:12 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

121.05% tõus

12 kuu keskmine prognoos

Keskmine 3.78 USD 121.05%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

146 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.